alpha Synuclein Recombinant Protein | SNCA recombinant protein

alpha Synuclein protein

Cat. Num. AAA836964

• Gene Names: SNCA; PD1; NACP; PARK1; PARK4
• Applications: SDS-Page
• Purity: > 95% pure
• Synonyms: alpha Synuclein; alpha Synuclein protein; PARK1 protein; NACP protein; MGC127560 protein; PARK 4 protein; alpha-Synuclein protein; PD1 protein; Non-A beta component of AD amyloid protein; alphaSYN protein; Non-A4 component of amyloid precursor protein; MGC105443 protein; PD 1 protein; MGC64356 protein; Non A4 component of amyloid precursor protein; SNCA protein; Synuclein alpha protein; MGC110988 protein; Parkinson disease familial 1 protein; Non-A-beta component of alzheimers disease amyloid protein; PARK4 protein; Non A beta component of AD amyloid protein; precursor of PARK 1 protein; Alpha-synuclein isoform NACP140 protein; Alpha synuclein protein; SNCA recombinant protein

• Host: Human
• Purity/Purification: > 95% pure
• Form/Format: Supplied as a liquid in 20 mM Tris-HCl buffer, pH 7.5, containing 0.1 M NaCl, and 1mM MgCl2.
• Concentration: 1 mg/ml (varies by lot)
• Sequence: MDVFMKGLSK AKEGVVAAAE KTKQGVAEAA GKTKEGVLYV GSKTKEGVVH GVATVAEKTK EQVTNVGGAV VTGVTAVAQK TVEGAGSIAA ATGFVKKDQL GKNEEGAPQE GILEDMPVDP DNEAYEMPSE EGYQDYEPEA
• Sequence Length: 13

• Applicable Applications for SNCA recombinant protein: SDS-PAGE
• Protein Type: Recombinant
• Biological Significance: alpha-Synuclein (amino acids 1-140), an acidic neuronal protein of 140 amino acids, is extremely heat-resistant and is natively unfolded with an extended structure primarily composed of random coils. alpha-synuclein has been suggested to be implicated in the pathogenesis of Parkinson?s disease and related neurodegenerative disorders, and more recently, to be an important regulatory component of vesicular transport in neuronal cells. Moreover, recent studies have shown that alpha-synuclein has chaperone activity and that this activity is lost upon removing its C-terminal acidic tail (amino acids 96-140).
• Endotoxin Levels: < 1.0 EU per ug of protein (determined by LAL method)
• Expression System: E Coli
• Preparation and Storage: Can be stored at 4 degree C short term (1-2 weeks). For long term storage, aliquot and store at -20C or -70C. Avoid repeated freezing and thawing cycles.

SDS-PAGE

(Figure annotation denotes ug of protein loaded and % gel used.)

Related Product Information for SNCA recombinant protein

Purified recombinant Human alpha Synuclein protein

Product Categories/Family for SNCA recombinant protein

Neuroscience

NCBI and Uniprot Product Information

• NCBI GI #: 46242542
• NCBI GeneID: 6622
• UniProt Accession #: Q6QBS3; P37840
• Molecular Weight: 14.4 kDa (140 aa), confirmed by MALDI-TOF. (Molecular weight on SDS-PAGE will appear higher)
• NCBI Official Full Name: alpha synuclein, partial
• NCBI Official Synonym Full Names: synuclein, alpha (non A4 component of amyloid precursor)
• NCBI Official Symbol: SNCA
• NCBI Official Synonym Symbols: PD1; NACP; PARK1; PARK4
• NCBI Protein Information: alpha-synuclein
• UniProt Protein Name: Alpha synuclein
• Protein Family: Alpha-synuclein
• UniProt Entry Name: Q6QBS3_HUMAN

NCBI Description

Alpha-synuclein is a member of the synuclein family, which also includes beta- and gamma-synuclein. Synucleins are abundantly expressed in the brain and alpha- and beta-synuclein inhibit phospholipase D2 selectively. SNCA may serve to integrate presynaptic signaling and membrane trafficking. Defects in SNCA have been implicated in the pathogenesis of Parkinson disease. SNCA peptides are a major component of amyloid plaques in the brains of patients with Alzheimer's disease. Four alternatively spliced transcripts encoding two different isoforms have been identified for this gene. [provided by RefSeq, Mar 2009]

Uniprot Description

SNCA: a member of the synuclein family. Abundantly expressed in the brain. Inhibits phospholipase D2 selectively. May integrate presynaptic signaling and membrane trafficking. Implicated in the pathogenesis of Parkinson's disease. A major component of amyloid plaques in the brains of patients with Alzheimer's disease. Two alternatively spliced isoforms transcripts have been identified.

Protein type: Adaptor/scaffold

Chromosomal Location of Human Ortholog: 4q21

Cellular Component: Golgi apparatus; nuclear outer membrane; mitochondrion; rough endoplasmic reticulum; lysosome; extracellular region; fibril; terminal button; inclusion body; cell cortex; mitochondrial respiratory chain complex I; cytosol; actin cytoskeleton; platelet alpha granule membrane; synaptic vesicle; growth cone; axon; perinuclear region of cytoplasm; cytoplasm; plasma membrane; ribosome; cell junction; nucleus

Molecular Function: identical protein binding; protein domain specific binding; histone binding; zinc ion binding; kinesin binding; microtubule binding; ferrous iron binding; caspase inhibitor activity; beta-tubulin binding; magnesium ion binding; protein N-terminus binding; phosphoprotein binding; calcium ion binding; Hsp70 protein binding; oxidoreductase activity; dynein binding; protein binding; phospholipase binding; copper ion binding; phospholipid binding; fatty acid binding; tau protein binding; alpha-tubulin binding

Biological Process: regulation of acyl-CoA biosynthetic process; positive regulation of apoptosis; adult locomotory behavior; response to lipopolysaccharide; positive regulation of endocytosis; dopamine biosynthetic process; positive regulation of neurotransmitter secretion; calcium ion homeostasis; response to magnesium ion; synapse organization and biogenesis; fibril organization and biogenesis; dopamine uptake; negative regulation of neuron apoptosis; response to drug; negative regulation of dopamine metabolic process; synaptic vesicle endocytosis; negative regulation of transporter activity; negative regulation of apoptosis; regulation of long-term neuronal synaptic plasticity; negative regulation of serotonin uptake; negative regulation of norepinephrine uptake; mitochondrial membrane organization and biogenesis; microglial cell activation; negative regulation of transcription from RNA polymerase II promoter; negative regulation of monooxygenase activity; negative regulation of caspase activity; fatty acid metabolic process; regulation of dopamine secretion; negative regulation of histone acetylation; negative regulation of dopamine uptake; negative regulation of exocytosis; negative regulation of protein amino acid phosphorylation; behavioral response to cocaine; phospholipid metabolic process; receptor internalization; response to iron(II) ion; positive regulation of receptor recycling; aging; caspase activation; neutral lipid metabolic process; protein destabilization; negative regulation of microtubule polymerization; regulation of macrophage activation; regulation of glutamate secretion; positive regulation of peptidyl-serine phosphorylation; organelle ATP synthesis coupled electron transport; regulation of locomotion; positive regulation of release of sequestered calcium ion into cytosol; regulation of excitatory postsynaptic membrane potential

Disease: Parkinson Disease 4, Autosomal Dominant; Dementia, Lewy Body; Parkinson Disease 1, Autosomal Dominant